source
- FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancerThe FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…
- FDA approves small-molecule dasatinib formulation, expanding CML treatment optionsDr Michael J. Mauro explained that the FDA gave its nod in November 2025 to a generic, small-molecule version of dasatinib, the drug sold as Sprycel, for adult patients with Philadelphia-positive c…